Tatva Chintan Pharma Chem Ltd - 543321 - Board Meeting Outcome for Outcome Of The Board Meeting Held On 05.05.2023
Outcome Of The Board Meeting Held On 05.05.202305-05-2023
05-05-2023
Tatva Chintan Pharma Chem Ltd - 543321 - Board Meeting Outcome for Outcome Of The Board Meeting Held On 05.05.2023
Outcome Of The Board Meeting Held On 05.05.202305-05-2023
Tatva Chintan Pharma Chem Ltd - 543321 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nippon Life India Trustee Ltd04-05-2023
Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, we would like to inform you that the Earnings Call post announcement of financial results of the Company for the quarter and financial year ended 31 March 2023, is scheduled on Friday, 05 May 2023 at 05:00 p.m. IST. The Call is hosted by ICICI Securities and an invite in this regard is attached for your information and records. The above information shall be uploaded on the website of the Company at www.tatvachintan.com.28-04-2023
Tatva Chintan Pharma Chem Ltd - 543321 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company Tatva Chintan Pharma Chem Ltd 2 CIN NO. L24232GJ1996PLC029894 3 Report filed for FY 2022-2023 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* FY 2022-23 and 2023-24 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)FY 2021-22 and 2022-23 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-ISHWAR NAYIDesignation :-Company Secretary and Compliance Officer Name of the Chief Financial Officer :- ASHOK BOTHRA Designation : -Chief Financial Officer Date: 28/04/202328-04-2023
Tatva Chintan Pharma Chem Ltd - 543321 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyTatva Chintan Pharma Chem Ltd 2CIN NO.L24232GJ1996PLC029894 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 14.05 4Highest Credit Rating during the previous FY A- 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: ISHWAR NAYI Designation: Company Secretary and Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: ASHOK BOTHRA Designation: Chief Financial Officer EmailId: [email protected] Date: 28/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.28-04-2023
Tatva Chintan Pharma Chem Ltd - 543321 - Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Friday, 05.05.2023
Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/05/2023 ,inter alia, to consider and approve 1. consider and approve and take on record the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended 31 March 2023; 2. consider and recommend a final dividend, if any, on the equity shares of the Company for the financial year ended 31 March 2023, subject to approval of the shareholders at the ensuing Annual General Meeting of the Company. Further, in accordance with the Company''s Code of Conduct for Prohibition of Insider Trading, the Company has intimated its ''''designated persons'''' regarding the closure of the Trading Window for trading in the Company''s equity shares from 01 April 2023 till the expiry of 48 hours from the date the said financial results are made public. The above information shall be uploaded on the website of the Company at www.tatvachintan.com. Kindly take above intimation on your record and oblige.25-04-2023
Tatva Chintan Pharma Chem Ltd - 543321 - Submission Of Certificate Under Regulation 40(9) & (10) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ended On 31 March 2023
Pursuant to Regulation 40(9) & (10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Certificate obtained from M/s. TNT & Associates, Practicing Company Secretaries for the year ended on 31 March 2023. Kindly take the above information on your record.12-04-2023
Tatva Chintan Pharma Chem Ltd - 543321 - Compliance Certificate Pursuant To Regulation 7(3) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015, For The Year Ended 31 March 2023
Compliance certificate pursuant to Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the year ended 31 March 2023.11-04-2023